68 results
6-K
EX-99.1
IPHA
Innate Pharma
14 May 24
Innate Pharma Reports First Quarter 2024 Business Update And Financial Results
6:07am
reported its consolidated financial results for the quarter ending March 31, 2024.
“We are executing our strategy of building on our partnered drug
6-K
EX-99.1
IPHA
Innate Pharma
21 Mar 24
Innate Pharma reports Full Year 2023 Financial Results and Business Update
6:01am
for combination strategy in this clinical indication.
The Phase 2 KILT (anti-KIR in T Cell Lymphoma) trial, an investigator-sponsored, randomized trial led
6-K
EX-99.01
qac0hjxy u7paw2a4up
6 Mar 24
Current report (foreign)
6:00am
424B5
gmf q5o2b05vibue
6 Feb 24
Prospectus supplement for primary offering
5:00pm
6-K
mfregisnozpf7z59
5 Jan 24
Innate Pharma S.a. 6-K
6:09am
6-K
EX-99.1
90rhef1qk hn4ytbh
4 Jan 24
Innate Pharma 6-K
6:00am
F-3
eawt53bj2
20 Dec 23
Shelf registration (foreign)
4:45pm
6-K
h0d6k9
20 Dec 23
Current report (foreign)
4:30pm
6-K
EX-99.1
b59xr
14 Nov 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
7df 8n1527f0j5n6i
7 Nov 23
Innate Pharma S.a. 6-K
6:01am
6-K
EX-99.2
hlp5xhk0qffhv2 3prm
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
ihscfysu10x 9c9nw9
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
hzadm1g5s4gwv9e
14 Sep 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
l1m5 edkjlfr65
12 Jun 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
mssbcpqtlw5p
3 May 23
Innate Pharma S.a. 6-K
6:01am
424B5
i9bos 804lz1
26 Apr 23
Prospectus supplement for primary offering
4:01pm
20-F/A
EX-4.9
9fqr6ubzpqgellue7bz
20 Apr 23
Annual report (foreign) (amended)
8:47am